Hero banner. Pluvicto▼ (lutetium Lu 177 vipivotide tetraxetan). Image of an older man with grey hair. Text: Pluvicto is available for eligible private patients in the United Kingdom.

This page is intended for UK healthcare professionals and other relevant decision makers only. If you are a member of the public, please click here.

This portal is funded and owned by Novartis Pharmaceuticals UK Ltd and includes content approved by Novartis.

Adverse events reporting information can be found in the footer of this page.

Welcome to the Radioligand Therapy Hub.

Please confirm whether you are a UK healthcare professional or a member of the public. This website is not suitable for healthcare professionals outside of the United Kingdom.

I am a UK Healthcare Professional

No, I am a member of the public

Search Results

RLT Home
Introduction to RLT
Neuroendocrine tumours
Prostate cancer

Popular Search

prrt
masterclass
part
2022
2023

Ask Speakers

Medical Information Request

Welcome to the Radioligand Therapy Hub.

Please confirm whether you are a UK healthcare professional or a member of public.

Yes, I am a UK healthcare professional

No, I am a member of the public

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard
Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report or alternatively email [email protected] or call 01276 698370.

Cookie Settings

Site directory

Novartis Pharmaceuticals UK Limited is a limited liability company registered in England and Wales under number 119006.
Registered office: The WestWorks Building, White City Place, 195 Wood Lane, London, W12 7FQ

UK | February 2025 | FA-11281060

This page is intended for UK healthcare professionals and other relevant decision makers only.

This portal is funded and owned by Novartis Pharmaceuticals UK Ltd and includes content approved by Novartis.